Ann: Suspension from Official Quotation, page-46

Agreed, it's price sensitive for a reason and I believe there's a good reason. I dont like to jump into conclusions, but i believe it's related to revenue improvement or something to do with NASDAQ/Hang Seng preparation. Yacouv's number 1 priority is Hang Seng listing, especially NASDAQ. Australia was just a vehicle for GMED to target ASIA . It was easier for GMED to IPO in Australia than any other place due to flexibility in our laws. I think there's a few people worried on here about company sinking down under, i dont personally believe that's the case. If this was an issue, they would have done a capital raise...

Biotech companies take time to develop and build that revenue, it's not an easy market to crack. I hold another unique company called Genetic Signatures (GSS) and I've been holding it  since day 1, GSS is unique and growing rapidly but has taken a lot of time.. They are ridiculously undervalue and if i was to compare the two companies, i can tell you that Yacouv progressed GMV rapidly for the past two years. Let's give credit where credit is due, this team is good. ...and have done very well. We have to hope for the best and wait for the report.